Research programme: cannabinoid therapeutics - Emerald/VivaCell

Drug Profile

Research programme: cannabinoid therapeutics - Emerald/VivaCell

Alternative Names: APH-1305; APH-1403; EHP 101; EHP 102; Neurodegenerative disease therapeutics - Aphios Corporation/VivaCell Biotechnology Espana; VCE-003; VCE-003.1; VCE-003.2; VCE-004; VCE-004.8; Δ9 Tetrahydrocannabinoid; Δ9 THCA

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aphios Corporation; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Developer Aphios Corporation; Emerald Health Sciences; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Class Cannabinoids; Quinones
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Fibrosis; Huntington's disease; Multiple sclerosis; Parkinson's disease; Scleroderma

Most Recent Events

  • 20 Oct 2017 EHP 101 receives Orphan Drug status for Systemic scleroderma in USA
  • 20 Oct 2017 Emerald Health Sciences plans a phase I trial for EHP 101 in USA in 2018
  • 20 Oct 2017 Emerald Health Sciences plans a phase II trial for Multiple sclerosis and Systemic scleroderma in USA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top